

Celiac Disease Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

https://marketpublishers.com/r/CAA506792153EN.html

Date: February 2025

Pages: 130

Price: US\$ 4,850.00 (Single User License)

ID: CAA506792153EN

Abstracts

The Global Celiac Disease Treatment Market was valued at USD 649.9 million in 2024 and is projected to expand at a CAGR of 10.6% from 2025 to 2034. The increasing prevalence of celiac disease and growing awareness among healthcare professionals regarding advanced diagnostic tools are driving the market. As more people are diagnosed due to improved detection methods, the demand for effective treatment continues to rise. Advancements in research and development are accelerating the introduction of pharmaceutical treatments, further propelling market expansion. The surge in gluten-free dietary preferences beyond the celiac population and the adoption of innovative non-invasive diagnostic tools are strengthening the industry. Technological advancements in HLA typing and antibody testing are enhancing diagnostic accuracy and reducing test duration, thereby increasing diagnosis rates and boosting demand for therapeutic solutions.

The market focuses on the management and treatment of celiac disease, an autoimmune disorder triggered by gluten ingestion in genetically predisposed individuals. It includes pharmaceutical products, supplements, and therapies designed to alleviate symptoms, prevent complications, and enhance patient well-being. The market is segmented into gluten-free diets, vitamin and mineral supplements, and medical therapies. The vitamins and minerals supplements category dominated, contributing USD 315.1 million in 2024, as celiac disease impairs nutrient absorption, necessitating supplementation to maintain health. Calcium and vitamin D intake is particularly emphasized for addressing bone health concerns associated with malabsorption.

Consumers are increasingly seeking specialized supplements that support gut health,



fueling market expansion. Based on administration routes, the market is divided into oral and parenteral treatments. The oral segment held a significant share of 63.4% in 2024, favored for its convenience, allowing patients to manage their condition without healthcare provider assistance. The introduction of novel oral formulations, including enzyme supplements and immune modulators, is broadening treatment options and improving patient adherence. These advancements enhance drug efficacy, bioavailability, and absorption, increasing adoption rates. Oral therapies remain preferred due to their ease of administration compared to injections and infusions, accommodating patients with busy lifestyles who require flexible treatment solutions.

The end-user market is classified into hospitals, specialty clinics, homecare settings, and other categories. Hospitals accounted for the largest segment in 2024, with projections reaching USD 904.1 million by 2034. The integration of therapeutic vaccines and anti-inflammatory drugs is expanding hospital-based treatment offerings. Advanced diagnostic tools and a diverse range of therapeutic options improve patient outcomes, increasing hospital admissions for disease management. Hospitals provide essential first-line treatments, including nutrition therapy, gluten-free diets, and biologics, which are not always available in primary care settings. The reliance on biologic agents and enzyme therapies drives frequent hospital visits, contributing to market growth.

In 2024, the United States dominated the North American market with a valuation of USD 260.3 million. Rising celiac disease cases are intensifying the demand for advanced treatments. The U.S. accounts for a significant portion of North American cases, highlighting an expanding patient base. Ongoing research into innovative treatment approaches, enhanced diagnostic systems, and strategic differentiation by key market players is fostering industry growth. Pharmaceutical advancements aim to mitigate immune system reactions, addressing one of the most pressing unmet medical needs.



Contents

CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market scope and definition
- 1.2 Research design
 - 1.2.1 Research approach
 - 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
 - 1.3.1 Base year calculation
 - 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
 - 1.5.1 Primary sources
 - 1.5.2 Data mining sources

CHAPTER 2 EXECUTIVE SUMMARY

2.1 Industry 360° synopsis

CHAPTER 3 INDUSTRY INSIGHTS

- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
 - 3.2.1 Growth drivers
 - 3.2.1.1 Rising prevalence of celiac disease
 - 3.2.1.2 Technological advancements in therapeutic options
 - 3.2.1.3 Increasing demand for gluten-free products
 - 3.2.1.4 Increasing diagnostic technologies for celiac disease diagnosis
 - 3.2.2 Industry pitfalls and challenges
 - 3.2.2.1 High cost of gluten-free products
 - 3.2.2.2 Stringent regulatory approvals
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Porter's analysis
- 3.6 PESTEL analysis

CHAPTER 4 COMPETITIVE LANDSCAPE, 2024



- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard

CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY TREATMENT, 2021 – 2034 (\$ MN)

- 5.1 Key trends
- 5.2 Vitamins and mineral supplements
- 5.3 Gluten-free diet
- 5.4 Medical therapies

CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY ROUTE OF ADMINISTRATION, 2021 – 2034 (\$ MN)

- 6.1 Key trends
- 6.2 Oral
- 6.3 Parenteral

CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY END USE, 2021 – 2034 (\$ MN)

- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Specialty clinics
- 7.4 Homecare settings
- 7.5 Other End Use

CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2034 (\$ MN)

- 8.1 Key trends
- 8.2 North America
 - 8.2.1 U.S.
 - 8.2.2 Canada
- 8.3 Europe
 - 8.3.1 Germany



- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.4 Asia Pacific
 - 8.4.1 China
 - 8.4.2 India
 - 8.4.3 Japan
 - 8.4.4 Australia
 - 8.4.5 South Korea
- 8.5 Latin America
 - 8.5.1 Brazil
 - 8.5.2 Mexico
 - 8.5.3 Argentina
- 8.6 Middle East and Africa
 - 8.6.1 South Africa
 - 8.6.2 Saudi Arabia
 - 8.6.3 UAE

CHAPTER 9 COMPANY PROFILES

- 9.1 ActoBio
- 9.2 Amgen
- 9.3 Amneal Pharmaceuticals
- 9.4 BioLineRx
- 9.5 Calypso Biotech
- 9.6 General Mills
- 9.7 Glenmark Life Sciences
- 9.8 Hikma Pharmaceuticals
- 9.9 Innovate Biopharmaceutical
- 9.10 Novartis
- 9.11 Takeda Pharmaceutical Company
- 9.12 Teva Pharmaceutical
- 9.13 Viatris
- 9.14 Zydus Pharmaceuticals



I would like to order

Product name: Celiac Disease Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis,

and Forecast 2025-2034

Product link: https://marketpublishers.com/r/CAA506792153EN.html

Price: US\$ 4,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/CAA506792153EN.html